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Cilostazol Significantly Reduces Restenosis in Diabetics With DES
Cilostazol has previously been shown to inhibit neointimal hyperplasia and reste-nosis after bare-metal stent implantation.Lee andcolleagues randomizeddiabetic
patients undergoing drug-eluting stent (DES) implantation to either sirolimus- or
paclitaxel-eluting stents, and to either standard therapy of aspirin and clopidogrel, or
standard therapy plus cilostazol. In-stent late lumen loss was significantly lower in the
cilostazol versus the standard group, as was 6-month in-segment restenosis (8% vs.
16%). In the 88 patients assigned to sirolimus-eluting stents and cilostazol, there was
no in-segment restenosis. Triple antiplatelet therapy with cilostazol after DES implan-
tation decreases angiographic restenosis and late loss, compared to standard dual
antiplatelet therapy in diabetic patients. See page 1181.
Page 1192
Coronary Artery Disease
NT-proBNP >500 pg/ml Predicts Increased
Mortality in ACS Patients With Negative Troponins
While an elevated troponin level is a strong marker of increased risk for patientswith acute coronary syndromes (ACS), further risk-stratifying chest pain pa-
tients with negative troponins has important prognostic implications. Weber and
colleagues measured N-terminal B-type natriuretic peptide (NT-proBNP) in over
2,500 troponin-negative (troponin T 0.01 ng/ml) patients from two different
registries with suspected ACS. In these 2 cohorts, an optimal cutoff value of 474 pg/ml
for NT-proBNP identified patients at higher risk. Patients with NT-proBNP levels
below this cutoff had 6monthmortality2%, comparedwith 8% to12% for patients
with higher BNP levels. This study suggests that measuring the NT-proBNP level can
substantially improve risk stratification of patients with chest pain orACS andnegative
troponin values. See page 1188. See figure.
Page 1200
Coronary Artery Disease
Circulating Lipid Hydroperoxides Predict Cardiovascular Events
Lipid hydroperoxides (LOOH) are generated from polyunsaturated fatty acids;LOOHmaybe furthermodified to generate reactive products thatmay lead to the
oxidationofLDLparticles.Walter and colleagues analyzedLOOHlevels frompatients
with stable coronary artery disease (CAD) who were followed for 3 years for clinical
events and angiographic progression of CAD. Subjects with baseline levels of LOOH
in the highest quartile were more than twice as likely to experience a nonfatal vascular
event or undergo amajor vascular procedure, andweremore likely to have progression
of CAD based on intravascular ultrasound studies. Circulating LOOH are indepen-
dently associatedwith cardiovascular risk andmaybe ausefulmarker of oxidative stress.
See page 1196. See figure.
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Mitral Surgery and Embolism
Risk of Stroke After Mitral Valve Surgery Varies With Type of Surgery
Russo and colleagues collected data on the incidence of stroke from over1,300 patients who underwent mitral valve surgery and were then fol-
lowed for 10 years. Two-thirds of patients had mitral valve repair (MRep); the
rest were evenly distributed between biologic and mechanical prostheses. The
5-year risk of stroke was lowest for MRep at 6%, compared to 8% for biologic
and 16% for mechanical. Most of this risk occurred in the first 30 days. After
30 days, those with either a MRep or a biologic prosthesis were not at increased
risk compared to a control population. Those with Mechanical valves were 5
times more likely to suffer a stroke, and had higher bleeding complications
compared to the control population. These results suggest that mitral valve
replacement with a mechanical prosthesis results in increased long-term risk of
stroke, whereas biologic replacements or MRep do not increase the long-term
risk of stroke, although there is substantial risk of perioperative stroke.
See page 1203. See figure.
